| Identification | Back Directory | [Name]
MR 2034 | [CAS]
57236-85-8 | [Synonyms]
MR 2034
(2R,11R)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-[[(R)-tetrahydrofuran-2-yl]methyl]-2α,6α-methano-3-benzazocin-8-ol
[2R,11R,(-)]-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-[[(R)-tetrahydrofuran-2-yl]methyl]-2α,6α-methano-3-benzazocin-8-ol | [Molecular Formula]
C19H27NO2 | [MOL File]
57236-85-8.mol | [Molecular Weight]
301.43 |
| Hazard Information | Back Directory | [Description]
MR2034 is a kappa-Opioid receptor agonist, stimulating hypothalamic-pituitary-adrenal axis. | [Uses]
MR2034 ((R)-UM-1071) is a κ-opioid receptor agonist with activity that stimulates the hypothalamic-pituitary-adrenal axis. MR2034 has shown the potential to promote mood and inhibit addictive behaviors in animal models and can be used to study inhibitory approaches related to mood and addictive disorders. MR2034 is selective for κ-opioid receptors and can effectively modulate biological processes related to stress and mood[1]. | [References]
[1] LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders DOI:10.1016/j.neuropharm.2013.09.021 |
|
|